Iloperidone
Active ingredient: Iloperidone
In short: Iloperidone tablets is indicated for: Treatment of schizophrenia in adults .
What is Iloperidone used for?
Iloperidone tablets is indicated for:
Treatment of schizophrenia in adults .
âš Boxed warning (FDA's strongest warning)
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Iloperidone is not approved for the treatment of patients with dementia-related psychosis.
Iloperidone dosage
Titrate Iloperidone to avoid orthostatic hypotension . Administer Iloperidone orally with or without food.
Indication and | Titration schedule | Recommended Dosage
Population | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7
Schizophrenia | 1mg twice daily | 2 mg twice daily | 4 mg twice daily | 6 mg twice daily | 8 mg twice daily | 10 mg twice daily | 12 mg twice daily | 6 mg to 12 mg twice daily
Reduce the dose of Iloperidone by one-half for CYP2D6 poor metabolizers . Table 2 includes dosage recommendations for Iloperidone in adults who are CYP2D6 poor metabolizers.
Indication and | Titration schedule | Recommended Dosage
Population | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7
Schizophrenia | 1mg twice daily | 2 mg twice daily | 4 mg twice daily | 6 mg twice daily | Titration complete | 3 mg to 6 mg twice daily
No dose adjustment for Iloperidone is needed in patients with mild hepatic impairment. Patients with moderate hepatic impairment may require dose reduction, if clinically indicated. Iloperidone is not recommended for patients with severe hepatic impairment .
Coadministration with Strong CYP2D6 Inhibitors
Reduce the dose of Iloperidone one-half when administered concomitantly with strong CYP2D6 inhibitors such as fluoxetine or paroxetine. When the CYP2D6 inhibitor is withdrawn from the combination therapy, increase the dose of Iloperidone to where it was before .
Coadministration with Strong CYP3A4 Inhibitors
Reduce the dose of Iloperidone by one-half when administered concomitantly with strong CYP3A4 inhibitors such as ketoconazole or clarithromycin. When the CYP3A4 inhibitor is withdrawn from the combination therapy, increase the dose of Iloperidone to where it was before .
Coadministration with Strong CYP2D6 and Strong CYP3A4 Inhibitors
Reduce the dose of Iloperidone by about one-half if administered concomitantly with inhibitors of CYP2D6 and CYP3A4. When both CYP2D6 and CYP3A4 inhibitors are withdrawn from the combination therapy, increase the dose of Iloperidone to where it was before .
Although there are no data to specifically address reinitiation of treatment, it is recommended that the initiation titration schedule be followed whenever patients have had an interval off Iloperidone of more than 3 days.
How to take Iloperidone — instructions & advice from the label
QT Interval Prolongation
Patients should be advised to consult their healthcare provider immediately if they feel faint, lose consciousness, or have heart palpitations. Patients should be counseled not to take Iloperidone tablets with other drugs that cause QT interval prolongation . Patients should be told to inform their healthcare provider that they are taking Iloperidone tablets before any new drug is taken.
Neuroleptic Malignant Syndrome (NMS)
Counsel patients and caregivers about a potentially fatal adverse reaction, NMS, that has been reported with administration of antipsychotic drugs, including Iloperidone tablets. Advise patients and caregivers to contact the healthcare provider or to report to the emergency room if they experience signs and symptoms of NMS .
Tardive Dyskinesia
Counsel patients on the signs and symptoms of tardive dyskinesia and to contact their healthcare provider if these abnormal movements occur .
Metabolic Changes
Educate patients of metabolic changes, how to recognize symptoms of hyperglycemia and diabetes mellitus, and the need for specific monitoring, including blood glucose, lipids, and weight. …
Warnings & precautions
Do not take this medicine if: Iloperidone is contraindicated in individuals with a known hypersensitivity reaction to the product. Anaphylaxis, angioedema, and other hypersensitivity reactions have been reported
.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 dementia-related psychosis placebo-controlled trials (modal duration of 10 weeks) largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in placebo-treated patients.
Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Iloperidone is not approved for the treatment of patients with dementia-related psychosis
.
In placebo-controlled trials in elderly subjects with dementia, patients randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. Iloperidone tablets is not approved for the treatment of patients with dementia-related psychosis .
.
In an open-label QTc study in patients with schizophrenia or schizoaffective disorder (n=160), Iloperidone was associated with QTc prolongation of 9 msec at an iloperidone dose of 12 mg twice daily. The effect of Iloperidone on the QT interval was augmented by the presence of CYP450 2D6 or 3A4 metabolic inhibition (paroxetine 20 mg once daily and ketoconazole 200 mg twice daily, respectively). …
Iloperidone side effects
The following adverse reactions are discussed in more detail in other sections of the labeling:
Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis
QT Prolongation
Neuroleptic Malignant Syndrome (NMS)
Tardive Dyskinesia
Metabolic Changes
Orthostatic Hypotension and Syncope
Falls
Seizures
Leukopenia, Neutropenia and Agranulocytosis
Hyperprolactinemia
Body Temperature Regulation
Dysphagia
Priapism
Potential for Cognitive and Motor Impairment
Intraoperative Floppy Iris Syndrome
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The information below is derived from a clinical trial database for Iloperidone consisting of 3,229 patients exposed to Iloperidone at doses of 10 mg/day or greater, for the treatment of schizophrenia of these, 999 received Iloperidone for at least 6 months, with 657 exposed to Iloperidone for at least 12 months for the treatment of schizophrenia. All of these patients who received Iloperidone were participating in multiple-dose clinical trials. …
Drug interactions
Table 7 presents clinically important drug interactions with Iloperidone.
Strong CYP2D6 Inhibitors
Clinical Impact | Coadministration of fluoxetine with iloperidone increased exposure (area under curve, [AUC]) of iloperidone and its metabolite P88, by about 2- to 3- fold, and decreased the AUC of its metabolite P95 by one-half
.
Coadministration of paroxetine with iloperidone resulted in increased mean steady- state peak concentrations of iloperidone and its metabolite P88, by about 1.6- fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half
.
Intervention | Reduce the dose of iloperidone by one-half when administered with strong CYP2D6 inhibitors. When a strong CYP2D6 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level
.
Strong CYP3A4 Inhibitors
Clinical Impact | Co-administration of ketoconazole with iloperidone, increased the AUC of iloperidone and its metabolites P88 and P95 by 57%, 55%, and 35%, respectively
.
Intervention | Reduce the dose of iloperidone by one-half when administered with strong CYP3A4 inhibitors. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level
. …
About this medicine
Iloperidone is an atypical antipsychotic belonging to the chemical class of piperidinyl-benzisoxazole derivatives. Its chemical name is 4'-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3'-methoxyacetophenone. Its molecular formula is C
24H
27FN
2O
4and its molecular weight is 426.48. The structural formula is:
Iloperidone is a white to off-white finely crystalline powder. It is practically insoluble in water, very slightly soluble in 0.1 N HCl and freely soluble in chloroform, ethanol, methanol, and acetonitrile.
Iloperidone tablets are intended for oral administration only. Each round, uncoated tablet contains 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, or 12 mg of iloperidone. Inactive ingredients are: colloidal silicon dioxide, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium bicarbonate and purified water (removed during processing). The tablets are white to off-white, round, flat with beveled edges uncoated tablet, debossed with
"050","051","052","053","054","055",or "056"on one side and plain on other side. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID eeb0fcfd-e4e8-4fb1-9635-901dc9446235. Read the full official label on DailyMed.
Related medicines
Sertraline Escitalopram Bupropion Fluoxetine Trazodone Duloxetine Prednisone Buspirone